Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
16.23
+0.01 (0.06%)
Jul 8, 2026, 4:00 PM EDT - Market closed
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 128 employees as of December 31, 2025. The number of employees decreased by 2 or -1.54% compared to the previous year.
Employees
128
Change (1Y)
-2
Growth (1Y)
-1.54%
Revenue / Employee
$2,330,430
Profits / Employee
$2,329,789
Market Cap
2.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -2 | -1.54% |
| Dec 31, 2024 | 130 | -170 | -56.67% |
| Dec 31, 2023 | 300 | 0 | - |
| Dec 31, 2022 | 300 | 0 | - |
| Dec 31, 2021 | 300 | 6 | 2.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| ADMA Biologics | 647 |
| Recursion Pharmaceuticals | 600 |
| Lakefront Biotherapeutics NV | 558 |
| Nuvation Bio | 307 |
| Monte Rosa Therapeutics | 187 |
| Stoke Therapeutics | 170 |
| Precigen | 160 |
AUPH News
- 2 days ago - Aurinia Pharmaceuticals announces initiation of PRESERVE study - TheFly
- 2 days ago - Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - Business Wire
- 4 weeks ago - Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis - TheFly
- 4 weeks ago - LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Business Wire
- 5 weeks ago - Aurinia Pharmaceuticals up 4% in pre-market after insider transactions - TheFly
- 2 months ago - Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c - TheFly
- 2 months ago - Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - Business Wire
- 2 months ago - Aurinia Pharmaceuticals Earnings release: Q1 2026 - Filings